Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-270 in MTAP-deleted Advanced Solid Tumors or Lymphoma
NCT03435250Phase 1Terminated
- Sponsor
- Servier
- Start
- Mar 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of S095033 in solid tumor (advanced stage), lymphoma, non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by Servier. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities (DLTs) Associated with AG-270 Administration at 28 days, Percentage of Participants with DLTs Associated with the Combination of AG-270 and Docetaxel at 28 days and 1 more. Started Mar 2018; status: terminated.
02
Drugs
S095033
03
Conditions
solid tumor (advanced stage)lymphomanon-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03435250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435250.